Why Metsera's Share Price Is Plummeting This Week
Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been rising higher all year and closed above $83 on Friday, Nov. 7, a high for the stock.
But on Monday of this week, it plummeted below $71, a 15% drop in a day. What's going on?
The big news for Metsera in recent weeks was a bidding war for the company between drug giants Novo Nordisk (NYSE: NVO) and (NYSE: PFE). One of the biggest and most rapidly growing markets for pharmaceutical companies today is the GLP-1 market, with drugs that effectively treat type 2 diabetes and obesity.
Source Fool.com
Pfizer Inc. Stock
€21.97
3.680%
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 27 € there is a positive potential of 22.92% for Pfizer Inc. compared to the current price of 21.97 €.
